You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博暉創新(300318.SZ)2021年度預虧2.7億-3.75億元 同比盈轉虧
格隆匯 01-21 18:06

格隆匯1月21日丨博暉創新(300318.SZ)公佈,預計2021年度歸屬於上市公司股東的淨虧損2.7億元-3.75億元,上年同期為盈利750.4萬元;扣除非經常性損益後的淨虧損2.81億元-3.86億元,上年同期為盈利385.95萬元。

報吿期公司歸屬於上市公司股東的淨利潤虧損,主要原因為:1、公司下屬控股孫公司中科生物製藥股份有限公司(“中科生物”)為了保證生產更好、更安全的生物藥品,正在對生產設施進行維修改造,2021年基本處於停產狀態,收入大幅下降,停工損失金額較大,對公司整體經營業績產生較大影響。

2、為夯實研發基礎、支持雲南血制項目建設,公司加大了研發投入及籌資力度,研發和財務費用同比增長,影響了公司經營業績。

3、計提商譽減值準備。一方面由於中科生物進行停產改造以及中科生物下屬籌建漿站運營資質的審批情況不及預期,導致公司控股子公司河北大安製藥有限公司收購中科生物形成的商譽存在減值跡象,公司進行了初步減值測試,並計提相應減值準備。另一方面,公司控股子公司常州領航量子生物醫療科技有限公司(“領航量子”)由於經營業績不及預期,導致公司收購領航量子形成的商譽存在減值跡象,公司進行了初步減值測試,並計提相應減值準備。經初步測算,以上商譽減值準備計提總額約為3.4億元,影響歸屬於上市公司股東的淨利潤約-2.4億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account